COVID‐19 in DMARD‐treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database

Abstract

Our results are in line with the literature on a potentially better safety profile for anti-IL-6 agents and JAK inhibitors. The WHO pharmacovigilance data suggest that COVID-19 is significantly more frequent in patients with IRDs treated with TNF inhibitors.